{"entity":{"id":"at101","kind":"drug","name":"AT101","aka":["AT101(Anti-CD19 Chimeric Antigen Receptor T cell)"],"tldr":"AT101 is an experimental CAR-T cell therapy from AbClon in phase 2 trials for hodgkin lymphoma, aimed at CD19.","summary":"AT101 is a CAR-T cell therapy developed by AbClon. Its target is CD19 (the sponsor names CD19). The sponsor states: Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells. ClinicalTrials.gov describes the intervention as: Anti-CD19 Chimeric Antigen Receptor T cell. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT05338931, plans to enrol 82 participants with primary completion expected 2030-03-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AT101","url":"https://clinicaltrials.gov/search?intr=AT101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["abclon"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05338931"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/at101/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"abclon","kind":"company","name":"AbClon","route":"/companies/abclon/"}],"trial":[{"id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","route":"/trials/nct05338931/"}]}}